Over the weekend, Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.

Source of Article

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year.

Source of Article

There's a growing body of evidence that gold nanoparticles can trigger significant weight loss that targets fat, without affecting muscles, plus heal organs and improve blood-glucose levels. A new study makes a strong case for the first-ever human trial.

Source of Article

Is obesity a disease or a risk factor for disease? It's a contentious question. In a new report, the Global Commission on Clinical Obesity strives to settle the enduring debate, introducing a new framework that seeks to redefine obesity.

Source of Article

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve physical functioning following weight loss, according to the results of a recent clinical trial by Novo Nordisk, the drug’s manufacturer.

Source of Article